# Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration.

> **NCT06180382** · PHASE4 · RECRUITING · sponsor: **Centre Hospitalier Universitaire de Saint Etienne** · enrollment: 220 (estimated)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** Adalimumab
- **DRUG:** Vedolizumab

## Key facts

- **NCT ID:** NCT06180382
- **Lead sponsor:** Centre Hospitalier Universitaire de Saint Etienne
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-31
- **Primary completion:** 2027-10-31
- **Final completion:** 2028-10-31
- **Target enrollment:** 220 (ESTIMATED)
- **Last updated:** 2026-05-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06180382

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06180382, "Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration.". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06180382. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*